
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
BrainLab, a developer of image-guided surgery and stereotactic radiosurgery systems, has sold its first BrainSuite to Staten Island University Hospital in New York City. The product combines image-guided surgery, intraoperative MRI data, visualization,
BrainLab, a developer of image-guided surgery and stereotactic radiosurgery systems, has sold its first BrainSuite to Staten Island University Hospital in New York City. The product combines image-guided surgery, intraoperative MRI data, visualization, and data management technology. BrainSuite should be operating by fall 2003.






